BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,339 | -13.7% | 19,653 | +3.4% | 0.00% | 0.0% |
| Q2 2023 | $1,551 | -5.2% | 19,002 | -13.8% | 0.00% | -25.0% |
| Q1 2023 | $1,636 | -17.5% | 22,054 | -7.8% | 0.00% | -20.0% |
| Q4 2022 | $1,983 | -99.9% | 23,907 | +372.2% | 0.01% | +25.0% |
| Q3 2022 | $1,437,000 | -5.0% | 5,063 | +15.9% | 0.00% | 0.0% |
| Q2 2022 | $1,513,000 | +1.3% | 4,367 | +26.7% | 0.00% | +33.3% |
| Q1 2022 | $1,493,000 | +40.2% | 3,447 | +67.5% | 0.00% | +50.0% |
| Q4 2021 | $1,065,000 | +90.5% | 2,058 | +78.2% | 0.00% | +100.0% |
| Q3 2021 | $559,000 | +12.2% | 1,155 | +4.3% | 0.00% | 0.0% |
| Q2 2021 | $498,000 | +21.5% | 1,107 | +3.2% | 0.00% | 0.0% |
| Q1 2021 | $410,000 | -26.5% | 1,073 | -38.9% | 0.00% | 0.0% |
| Q4 2020 | $558,000 | +29.8% | 1,757 | +1.2% | 0.00% | 0.0% |
| Q3 2020 | $430,000 | -68.9% | 1,737 | -66.8% | 0.00% | -75.0% |
| Q2 2020 | $1,382,000 | +1228.8% | 5,231 | +852.8% | 0.00% | – |
| Q1 2020 | $104,000 | -14.0% | 549 | 0.0% | 0.00% | – |
| Q4 2019 | $121,000 | +13.1% | 549 | 0.0% | 0.00% | – |
| Q3 2019 | $107,000 | -6.1% | 549 | 0.0% | 0.00% | – |
| Q2 2019 | $114,000 | +1325.0% | 549 | +1207.1% | 0.00% | – |
| Q1 2019 | $8,000 | -95.6% | 42 | -96.7% | 0.00% | -100.0% |
| Q4 2018 | $182,000 | -26.9% | 1,259 | +3.0% | 0.00% | 0.0% |
| Q3 2018 | $249,000 | +8.3% | 1,222 | -21.2% | 0.00% | 0.0% |
| Q2 2018 | $230,000 | -59.9% | 1,550 | -59.2% | 0.00% | -50.0% |
| Q1 2018 | $574,000 | -40.1% | 3,798 | -48.7% | 0.00% | -50.0% |
| Q4 2017 | $959,000 | +8.7% | 7,406 | +1.4% | 0.00% | 0.0% |
| Q3 2017 | $882,000 | -4.1% | 7,306 | -6.7% | 0.00% | 0.0% |
| Q2 2017 | $920,000 | +15.7% | 7,830 | 0.0% | 0.00% | +33.3% |
| Q1 2017 | $795,000 | -2.9% | 7,830 | -1.8% | 0.00% | -25.0% |
| Q4 2016 | $819,000 | -4.8% | 7,970 | +1.4% | 0.00% | 0.0% |
| Q3 2016 | $860,000 | -2.9% | 7,859 | 0.0% | 0.00% | -20.0% |
| Q2 2016 | $886,000 | +19.1% | 7,859 | -0.2% | 0.01% | +25.0% |
| Q1 2016 | $744,000 | +41.4% | 7,876 | +34.7% | 0.00% | +33.3% |
| Q4 2015 | $526,000 | +2668.4% | 5,845 | +2696.7% | 0.00% | – |
| Q3 2015 | $19,000 | -5.0% | 209 | +3.5% | 0.00% | – |
| Q2 2015 | $20,000 | +53.8% | 202 | +53.0% | 0.00% | – |
| Q1 2015 | $13,000 | -18.8% | 132 | -23.3% | 0.00% | – |
| Q4 2014 | $16,000 | – | 172 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |